Loading resource…

UpToDate
This document summarizes recent developments and evidence-based updates across various medical fields. It covers surgical innovations such as the use of mesh in rectus abdominis diastasis repair and laparoscopic groin hernia repair, discussing the comparative outcomes of different mesh types. Additionally, it references clinical trials for gonorrhoea treatments, updates on HPV vaccine efficacy, and hormonal therapies. The document also highlights risk factors for severe COVID-19, including age, comorbidities, and socioeconomic factors, and mentions considerations for choosing pre-exposure prophylaxis (PrEP) regimens.
No account needed
Severe Haemophilia: Marstacimab Reduced Bleeding, but Thrombosis Was Reported
“Marstacimab is a monoclonal antibody against tissue factor pathway inhibitor (TFPI) that can be used for bleed prevention in hemophilia A or B, but evidence for its efficacy has been limited. In the BASIS study, 116 males with severe hemophilia A or B were treated with marstacimab 150 mg subcutaneously once per week for one year. Annualized bleeding rates decreased from 8 to 5 in those previously receiving factor prophylaxis and from 40 to 3 in those previously receiving on-demand factor. There were no unexpected adverse events, with the exception of one unpublished case of venous thrombosis in an individual with other thrombotic risk factors.”